MarketPulse
C

$CTMX

2 articles found
1 positive
0 negative
1 neutral
The Motley FoolThe Motley Fool··Jack Delaney

Small-Cap Biotech vs. Pharma Giants: Navigating Risk and Reward in Healthcare

Small-cap biotech like CTMX offers explosive growth potential but carries significant risk; megacap pharma like JNJ provides stability and dividends with moderate returns.
JNJCTMXstock volatilityportfolio diversification
GlobeNewswire Inc.GlobeNewswire Inc.··Cytomx Therapeutics, Inc.

CytomX Raises $250M via Stock Offering to Fund Varseta-M Development

CytomX Therapeutics prices $250M stock offering at $5.30/share to fund Varseta-M development and pipeline advancement, closing March 2026.
AMGNBMYCELGrREGNMRNA+1colorectal cancerpublic offering